Nuclear Pharmacy Market Growth Analysis and Key Drivers in Oncology and Cardiology Applications

The Nuclear Pharmacy Market Size is valued at USD 6.27 Bn in 2024 and is predicted to reach USD 17.96 Bn by the year 2034 at a 11.2 % CAGR during the forecast period for 2025-2034.

Global Nuclear Pharmacy Market 2025-2034 full Research Repot latest version is now available.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1980

Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global Nuclear Pharmacy market are:
• Increasing incidence and prevalence of target conditions
• Increasing Applications in Oncology and Cardiology
• Rising Prevalence of Chronic Diseases

The following are the primary obstacles to the Nuclear Pharmacy market's expansion:
• Technological Complexities and Infrastructure Requirements
• Supply Chain Disruptions and Radiopharmaceutical Shortages
• Short half-life of radiopharmaceuticals

Future expansion opportunities for the global Nuclear Pharmacy market include:
• Growing Demand for Personalized Medicine
• Advancements in Nuclear Medicine Technologies
• Technological Innovations in Radiopharmaceutical Production

Key Industry Insights & Findings from the report:
• The industry is expanding as technology advancements allow radiopharmaceuticals to be used to identify and treat malignant tumors. The increasing prevalence of cancer and cardiovascular disorders, advances in radiopharmaceuticals, and the growing usage of nuclear medicine in diagnostic and therapeutic applications are the key drivers of the nuclear medicine market.
• The increased government funding for nuclear medical research and development will drive market growth.
• A chronic shortage of skilled healthcare professionals impedes the use of nuclear pharmacy technologies.
• North America is expected to have the largest market share in 2024 due to an increase in surgical procedures and a rise in preference for endovascular devices.

Market Analysis:
The Global Nuclear Pharmacy Market has experienced growth driven by several key factors, including the increasing prevalence of chronic diseases, advancements in nuclear medicine technology, and a rising demand for personalized medicine. The market's expansion is further supported by regulatory approvals for new radiopharmaceuticals, the broadened use of nuclear medicine in oncology and neurology, and enhanced investment in nuclear medicine infrastructure. Additionally, strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers are working to accelerate product development, optimize distribution channels, and improve patient access to nuclear medicine services on a global scale.

List of Prominent Players in the Nuclear Pharmacy Market:
• GE HealthCare
• Cardinal Health
• Curium
• Bayer AG
• Lantheus Holdings, Inc.
• Bracco Imaging S.p.A.
• PharmaLogic Holdings Corp.
• Eczacibasi-Monrol Nuclear Products
• NTP Radioisotopes SOC Ltd
• Nordion Inc.
• Novartis (Advanced Accelerator Application)
• NorthStar Medical Radioisotopes
• Eckert & Ziegler
• Isotope JSC
• Siemens Healthineers

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Recent Developments:
• In January 2023, NorthStar Medical Radioisotopes (US) has made significant progress in developing its novel method for producing molybdenum-99 (Mo-99), a crucial medical radioisotope, without using uranium.
• In May 2024, Mauritius launched its new National Cancer Centre in Solferino, marking the completion of nearly 10 years of IAEA support for the country's nuclear medicine development. The new center is expected to drastically change cancer care for Mauritius patients by consolidating all oncology services, including nuclear medicine, under one roof.
• In January 2023, NorthStar Medical Radioisotopes significantly improved their process to create molybdenum-99 without uranium. This strategic move propels the organization to the forefront of the nuclear medicine market while solving important supply chain challenges.

Nuclear Pharmacy Market Dynamics:
Market Drivers: Increasing Prevalence of Targeted Conditions
The growing incidence of cancer and cardiovascular diseases is a significant factor propelling the expansion of the market. Early detection and treatment of these conditions are often critical, and nuclear medicine plays a vital role in both areas. According to the American Heart Association (2022), approximately 19.1 million deaths worldwide in 2020 were attributed to cardiovascular diseases (CVD). The age-adjusted mortality rate was 239.8 per 100,000 population, while the age-adjusted prevalence rate stood at 7354.1 per 100,000. As the prevalence of these diseases continues to rise, the demand for nuclear medicine for diagnosis and treatment is expected to drive market growth during the forecast period.

Challenges: Technological and Infrastructure Barriers
Technological challenges and the need for specialized infrastructure present significant obstacles in the global nuclear pharmacy market, particularly in emerging economies and resource-limited areas. The production and delivery of radiopharmaceuticals require specialized facilities, equipment, and expertise to ensure safe handling, synthesis, quality control, and distribution of radioactive drugs. Establishing and maintaining nuclear pharmacy, cyclotron, and radioisotope production facilities necessitate substantial capital investment, regulatory approvals, and specialized operational knowledge.

North America Expected to Exhibit Highest Growth Rate
North America is projected to maintain a leading position in the global nuclear pharmacy market, driven by several factors. The region boasts advanced healthcare infrastructure, including extensive networks of hospitals, clinics, and academic medical institutions equipped with state-of-the-art imaging technologies and nuclear medicine capabilities. This infrastructure enables widespread adoption of nuclear medicine for diagnostic imaging, treatment, and medical research, resulting in increased demand for radiopharmaceuticals and nuclear pharmacy services, and contributing to the region's high growth rate during the forecast period.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1980

Segmentation of Nuclear Pharmacy Market-
By Type-
• Diagnostic Nuclear Medicine
o SPECT Radiopharmaceuticals
 Tc-99m
 1-123
 Tl-201
 Ga-67
 Other SPECT Isotopes
o PET Radiopharmaceuticals
 F-18
 Rb-82
 Other PET Isotopes
• Therapeutic Nuclear Medicine
o Alpha Emitters
 Ra-223
o Beta Emitters
 1-131
 Y-90
 Sm-153
 Lu-177
 Re-186
 Other Beta Emitters
• Brachytherapy Isotopes
o 1-125
o Ir-192
o Pd-103
o Cs-131
o Other Brachytherapy Isotopes
By Application-
• Diagnostic Applications
o SPECT Applications
 Cardiology
 Bone Scans
 Thyroid Applications
 Pulmonary Scans
 Other SPECT Applications
• PET Applications
o Oncology
o Cardiology
o Neurology
o Other PET Applications
• Therapeutic Applications
o Thyroid Indications
o Bone Metastasis
o Lymphoma
o Endocrine Tumors
o Other Indications
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/nuclear-pharmacy-market/1980

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.